1.00p
0.00%
Close of 9 Nov 2026, in pence
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About BSF Enterprise
Its shares trade on LSE under the ticker BSFA.L. It has been listed since 26 July 2019. In the fiscal year to 30 September 2025, it reported revenue of £52,840 and a net loss of £1.1m. At that date it held total assets of £3.0m and shareholders' equity of £2.7m.
BSF Enterprise Plc engages in identifying investment opportunities within the innovation marketing and technology sector. The firm is focused on developing biotechnological solutions using cell-based tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes. The firm operates through its wholly owned subsidiary, 3D Bio-Tissues Limited (3DBT), which is a clinical and cellular agriculture company engaged in producing human corneas that could help restore vision to millions of people. 3DBT has three strands of three intellectual property (IP) each with a different sector focus development and revenue timeline. 3DBT’s City-mix is an animal-free cell growth agent for culturing skin, muscle and fat cells which are used for lab-grown meat and leather production. 3DBT’s Lipopeptide Etsyl actively increases collagen production in human skin cells which can be used in cosmetic and skin care products.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 26 Jul 2019
- Employees
- 3
- Website
- bsfenterprise.com ↗
Leadership
Pay as last reported
- Prof. Dr. Che ConnonChief Executive Officer, Executive Director, since 2022£130,000
- Mr. Geoffrey BakerExecutive Director, Company Secretary, since 2019£92,000
- Mr. Kian Jing OwIndependent Non-Executive Director£30,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- BSF Enterprise PLC focuses on innovative biotechnological solutions for cultured meat and lab-grown leather production.
- 3D Bio-Tissues Limited develops human corneas to restore vision for millions of people.
- 3DBT's City-mix supports animal-free cell growth for lab-grown meat and leather applications.
Weaknesses
- BSF Enterprise PLC has only three employees as of the latest data.
- 3D Bio-Tissues Limited operates with three intellectual property strands.
- The company's business model relies on a single subsidiary, 3DBT.
Opportunities
- BSF Enterprise PLC can expand its biotechnological solutions into new markets like cosmetic skincare.
- 3DBT's Lipopeptide Etsyl offers potential for growth in the cosmetic industry.
- The global demand for lab-grown meat and leather presents significant market opportunities.
Threats
- BSF Enterprise PLC faces competition from established biotechnology firms in the health care sector.
- 3D Bio-Tissues Limited must navigate regulatory challenges for human cornea production.
- The company's reliance on a single subsidiary increases vulnerability to operational risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.